May 16, 2022
VIA EDGAR
Michael Davis
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Landos Biopharma, Inc. |
Registration Statement on Form S-3; File No. 333-263836
Acceleration Request
Requested Date: Wednesday, May 18, 2022
Requested Time: 4:00 p.m. Eastern Time
Dear Mr. Davis:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263836) (the “Registration Statement”) to become effective on Wednesday, May 18, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043, or in her absence, Madison Jones at (202) 728-7087.
| Very truly yours, | ||
| LANDOS BIOPHARMA, INC. | ||
| By: | /s/ Tim M. Mayleben | |
| Tim M. Mayleben | ||
| Chief Executive Officer | ||